Stockscreener 앱 받기
15.96
5.14%
0.78
전일 마감가:
$15.18
열려 있는:
$15.13
하루 거래량:
45,161
Relative Volume:
0.30
시가총액:
$144.38M
수익:
$123.24M
순이익/손실:
$136.00K
주가수익비율:
-798.00
EPS:
-0.02
순현금흐름:
$-148.99M
1주 성능:
+1.98%
1개월 성능:
-1.48%
6개월 성능:
+14.24%
1년 성능:
+8.57%
1일 변동 폭
$15.07
$16.05
1주일 범위
$14.90
$16.42
52주 변동 폭
$6.53
$29.98
Seres Therapeutics Inc Stock (MCRB) Company Profile
명칭
Seres Therapeutics Inc
전화
617 945 9626
주소
200 SIDNEY STREET, CAMBRIDGE, MA
MCRB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
15.96 | 137.33M | 123.24M | 136.00K | -148.99M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-08 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2024-10-24 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-04-21 | 개시 | JP Morgan | Neutral |
| 2021-07-23 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-03-05 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2020-09-18 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2020-08-18 | 개시 | Piper Sandler | Overweight |
| 2020-08-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-11 | 업그레이드 | Jefferies | Hold → Buy |
| 2019-04-30 | 개시 | Jefferies | Hold |
| 2018-10-22 | 개시 | Chardan Capital Markets | Buy |
| 2017-10-13 | 개시 | Oppenheimer | Outperform |
| 2017-08-04 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-01 | 재확인 | FBR & Co. | Outperform |
| 2016-08-12 | 재확인 | FBR Capital | Outperform |
| 2016-08-01 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2016-08-01 | 재확인 | H.C. Wainwright | Buy |
| 2016-07-29 | 재개 | H.C. Wainwright | Buy |
| 2016-03-30 | 개시 | FBR Capital | Outperform |
| 2016-03-03 | 개시 | Guggenheim | Buy |
| 2016-01-25 | 개시 | H.C. Wainwright | Buy |
| 2015-10-22 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2015-07-22 | 개시 | Canaccord Genuity | Buy |
| 2015-07-21 | 개시 | Goldman | Neutral |
| 2015-07-21 | 개시 | Leerink Partners | Outperform |
모두보기
Seres Therapeutics Inc 주식(MCRB)의 최신 뉴스
Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below 50 Day Moving Average – Time to Sell? - Defense World
Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below 50 Day Moving AverageTime to Sell? - MarketBeat
Aug Retail: Is Pro Dex Inc benefiting from interest rate changesWeekly Market Report & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Chart Watch: Can Seres Therapeutics Inc weather a recessionEarnings Risk Summary & High Accuracy Trade Alerts - baoquankhu1.vn
Whats next for Seres Therapeutics Inc stockMarket Sentiment Summary & Smart Allocation Stock Reports - baoquankhu1.vn
Aug Momentum: Will Seres Therapeutics Inc. stock deliver better than expected guidance2025 Top Gainers & Capital Efficient Trading Techniques - Bộ Nội Vụ
Will Seres Therapeutics Inc. stock deliver better than expected guidanceWeekly Market Summary & Free High Accuracy Swing Entry Alerts - Улправда
Seres Therapeutics, Inc.Common Stock (NQ: MCRB - FinancialContent
Published on: 2026-01-13 00:08:06 - ulpravda.ru
Seres Therapeutics publishes new insights on VOWST mechanism By Investing.com - Investing.com Nigeria
Why Seres Therapeutics Inc. stock is in analyst buy zone2026 world cup usa national team final playmakers low block defense expert forecast expert opinion - Улправда
Seres Therapeutics expands board, appoints new director - MSN
Seres Therapeutics publishes new insights on VOWST mechanism - Investing.com
Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy - GlobeNewswire
Seres Therapeutics Q1 2025 Earnings Preview - MSN
Why Seres Therapeutics Inc. stock is rated strong buyInterest Rate Changes & Minimal Risk High Reward - bollywoodhelpline.com
Seres Therapeutics (NASDAQ:MCRB) Stock Price Passes Below 50-Day Moving AverageHere's Why - MarketBeat
3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround - The Globe and Mail
How Seres Therapeutics Inc. stock responds to policy changesGlobal Markets & Verified Entry Point Detection - Улправда
The Great Biotech Re-Shoring: Seres Therapeutics and the New Commodity-Driven Era - FinancialContent
Can Seres Therapeutics Inc. (1S90) stock stage a strong rebound this quarterMarket Volume Report & Fast Gain Swing Alerts - DonanımHaber
Why analysts remain bullish on Seres Therapeutics Inc. stockRate Cut & Daily Profit Focused Stock Screening - DonanımHaber
Is Seres Therapeutics Inc. stock affected by interest rate hikesCPI Data & Weekly Return Optimization Alerts - Улправда
Will Seres Therapeutics Inc. stock gain from government policiesJuly 2025 Market Mood & Weekly Top Stock Performers List - Улправда
Seres Therapeutics Cuts Costs to Extend Cash Runway - MSN
Head-To-Head Contrast: Castle Biosciences (NASDAQ:CSTL) versus Seres Therapeutics (NASDAQ:MCRB) - Defense World
North America Human Microbiome Market Size & Growth Forecast to 2031 - MarketsandMarkets
Guidance Update: How Seres Therapeutics Inc 1S90 stock compares with market leaders2025 Biggest Moves & Long-Term Growth Stock Strategies - moha.gov.vn
Published on: 2025-12-13 20:57:20 - moha.gov.vn
Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Above 50 Day Moving AverageHere's What Happened - MarketBeat
Seres Therapeutics (MCRB) price target increased by 31.25% to 21.42 - MSN
Seres Therapeutics, Inc. (MCRB) 5.04% in After-hours: What’s Driving the Move? - Stocks Telegraph
Seres Therapeutics Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
Seres Therapeutics (NASDAQ:MCRB) Stock Passes Below 50 Day Moving Average – Here’s What Happened - Defense World
Seres Therapeutics (MCRB) Price Target Increased by 31.25% to 21.42 - Nasdaq
What risks investors should watch in Seres Therapeutics Inc. stockQuarterly Growth Report & Accurate Intraday Trading Signals - Newser
Seres Therapeutics (NASDAQ:MCRB) Stock Passes Below 50 Day Moving AverageHere's What Happened - MarketBeat
Will Seres Therapeutics Inc. (1S90) stock outperform foreign stocksWeekly Risk Summary & Real-Time Chart Pattern Alerts - Newser
Will Seres Therapeutics Inc. (1S90) stock beat value stocks2025 Year in Review & Verified Chart Pattern Signals - Newser
What market sentiment indicators show for Seres Therapeutics Inc. (1S90) stock2025 Institutional Moves & Free Daily Entry Point Trade Alerts - Newser
Is Seres Therapeutics Inc. stock dividend yield sustainablePortfolio Update Report & Growth Oriented Trade Recommendations - Newser
Is Seres Therapeutics Inc. stock positioned for long term growth2025 Support & Resistance & Growth Focused Stock Pick Reports - Newser
Seres Therapeutics (MCRB) Stock Analysis Report | Financials & Insights - Benzinga
Seres Therapeutics Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis
Volatility Watch: Why Seres Therapeutics Inc. stock is rated strong buyJuly 2025 Review & High Accuracy Trade Alerts - Bộ Nội Vụ
Seres Therapeutics Inc (MCRB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):